BAAM
VNDA icon

Baker Avenue Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Baker Avenue Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$1.36K – 1772
2023
Q1 		$1.36K Buy
+200
New +$1.41K ﹤0.01% 1088

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Baker Avenue Asset Management's VNDA Position: Q2 2023 in Review

Baker Avenue Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2023, closing a stake of 200 shares — an estimated $1.36K sold.

Baker Avenue Asset Management first reported a position in VNDA in Q1 2023 and held it in 1 quarter. The position peaked at $1.36K in Q1 2023. 188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

  • Baker Avenue Asset Management reported no remaining Vanda Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 200 Vanda Pharmaceuticals shares in Q2 2023, an estimated $1.36K.
  • Baker Avenue Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Vanda Pharmaceuticals position peaked at $1.36K in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on Baker Avenue Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.